Literature DB >> 9916080

Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA.

D C Lowe1, T C Savidge, D Pickard, L Eckmann, M F Kagnoff, G Dougan, S N Chatfield.   

Abstract

The properties of two candidate Salmonella typhi-based live oral typhoid vaccine strains, BRD691 (S. typhi Ty2 harboring mutations in aroA and aroC) and BRD1116 (S. typhi Ty2 harboring mutations in aroA, aroC, and htrA), were compared in a number of in vitro and in vivo assays. BRD1116 exhibited an increased susceptibility to oxidative stress compared with BRD691, but both strains were equally resistant to heat shock. Both strains showed a similar ability to invade Caco-2 and HT-29 epithelial cells and U937 macrophage-like cells, but BRD1116 was less efficient at surviving in epithelial cells than BRD691. BRD1116 and BRD691 were equally susceptible to intracellular killing within U937 cells. Similar findings were demonstrated in vivo, with BRD1116 being less able to survive and translocate to secondary sites of infection when inoculated into the lumen of human intestinal xenografts in SCID mice. However, translocation of BRD1116 to spleens and livers in SCID mice occurred as efficiently as that of BRD691 when inoculated intraperitonally. The ability of BRD1116 to increase the secretion of interleukin-8 following infection of HT-29 epithelial cells was comparable to that of BRD691. Therefore, loss of the HtrA protease in S. typhi does not seem to alter its ability to invade epithelial cells or macrophages or to induce proinflammatory cytokines such as IL-8 but significantly reduces intracellular survival in human intestinal epithelial cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916080      PMCID: PMC96376          DOI: 10.1128/IAI.67.2.700-707.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.

Authors:  D M Hone; C O Tacket; A M Harris; B Kay; G Losonsky; M M Levine
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  The role of a stress-response protein in Salmonella typhimurium virulence.

Authors:  K Johnson; I Charles; G Dougan; D Pickard; P O'Gaora; G Costa; T Ali; I Miller; C Hormaeche
Journal:  Mol Microbiol       Date:  1991-02       Impact factor: 3.501

3.  Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model.

Authors:  S N Chatfield; K Strahan; D Pickard; I G Charles; C E Hormaeche; G Dougan
Journal:  Microb Pathog       Date:  1992-02       Impact factor: 3.738

4.  Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

Authors:  C O Tacket; D M Hone; G A Losonsky; L Guers; R Edelman; M M Levine
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

5.  Intracellular replication is essential for the virulence of Salmonella typhimurium.

Authors:  K Y Leung; B B Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

6.  Construction of genetically defined double aro mutants of Salmonella typhi.

Authors:  D M Hone; A M Harris; S Chatfield; G Dougan; M M Levine
Journal:  Vaccine       Date:  1991-11       Impact factor: 3.641

7.  Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.

Authors:  R Strugnell; G Dougan; S Chatfield; I Charles; N Fairweather; J Tite; J L Li; J Beesley; M Roberts
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

Authors:  C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

9.  Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine.

Authors:  S N Chatfield; I G Charles; A J Makoff; M D Oxer; G Dougan; D Pickard; D Slater; N F Fairweather
Journal:  Biotechnology (N Y)       Date:  1992-08

10.  Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine.

Authors:  S N Chatfield; N Fairweather; I Charles; D Pickard; M Levine; D Hone; M Posada; R A Strugnell; G Dougan
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

View more
  21 in total

1.  aro mutations in Salmonella enterica cause defects in cell wall and outer membrane integrity.

Authors:  Alena Sebkova; Daniela Karasova; Magdalena Crhanova; Eva Budinska; Ivan Rychlik
Journal:  J Bacteriol       Date:  2008-02-29       Impact factor: 3.490

Review 2.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

3.  Transcriptional activation of the htrA (High-temperature requirement A) gene from Bartonella henselae.

Authors:  S I Resto-Ruiz; D Sweger; R H Widen; N Valkov; B E Anderson
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Protection mediated by antibodies to iron-regulated outer-membrane proteins of S. typhi in a mouse peritonitis model.

Authors:  Shaloo Sood; Praveen Rishi; Veena Dhawan; Saroj Sharma; Nirmal Kumar Ganguly
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

5.  Analysis of the hypervariable region of the Salmonella enterica genome associated with tRNA(leuX).

Authors:  Anne L Bishop; Stephen Baker; Sara Jenks; Maria Fookes; Peadar O Gaora; Derek Pickard; Muna Anjum; Jeremy Farrar; Tran T Hien; Al Ivens; Gordon Dougan
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

6.  Rapid method for the construction of Salmonella enterica Serovar Typhimurium vaccine carrier strains.

Authors:  Mohamed I Husseiny; Michael Hensel
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

7.  Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis.

Authors:  V Foulongne; G Bourg; C Cazevieille; S Michaux-Charachon; D O'Callaghan
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Authors:  C O Tacket; M B Sztein; S S Wasserman; G Losonsky; K L Kotloff; T L Wyant; J P Nataro; R Edelman; J Perry; P Bedford; D Brown; S Chatfield; G Dougan; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  Aromatic compound-dependent Brucella suis is attenuated in both cultured cells and mouse models.

Authors:  V Foulongne; K Walravens; G Bourg; M L Boschiroli; J Godfroid; M Ramuz; D O'Callaghan
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

10.  Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium.

Authors:  S J McSorley; M K Jenkins
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.